These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 11735670)

  • 21. A surveillance programme for Barrett's oesophagus in a UK general hospital.
    Olithselvan A; Gorard DA; McIntyre AS
    Eur J Gastroenterol Hepatol; 2007 Apr; 19(4):305-9. PubMed ID: 17353694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk.
    Provenzale D; Schmitt C; Wong JB
    Am J Gastroenterol; 1999 Aug; 94(8):2043-53. PubMed ID: 10445526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
    Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
    Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Should patients with Barrett's oesophagus be kept under surveillance? The case for.
    Armstrong D
    Best Pract Res Clin Gastroenterol; 2008; 22(4):721-39. PubMed ID: 18656826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Barrett's surveillance is worthwhile and detects curable cancers. A prospective cohort study addressing cancer incidence, treatment outcome and survival.
    Aldulaimi DM; Cox M; Nwokolo CU; Loft DE
    Eur J Gastroenterol Hepatol; 2005 Sep; 17(9):943-50. PubMed ID: 16093872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett's esophagus.
    Das A; Wells C; Kim HJ; Fleischer DE; Crowell MD; Sharma VK
    Endoscopy; 2009 May; 41(5):400-8. PubMed ID: 19418393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial.
    Fitzgerald RC; di Pietro M; O'Donovan M; Maroni R; Muldrew B; Debiram-Beecham I; Gehrung M; Offman J; Tripathi M; Smith SG; Aigret B; Walter FM; Rubin G; ; Sasieni P
    Lancet; 2020 Aug; 396(10247):333-344. PubMed ID: 32738955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surveillance for Barrett's oesophagus: results from a programme in Northern Ireland.
    Murphy SJ; Dickey W; Hughes D; O'Connor FA
    Eur J Gastroenterol Hepatol; 2005 Oct; 17(10):1029-35. PubMed ID: 16148547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The rationale for screening and surveillance of Barrett's metaplasia.
    Wani S; Sharma P
    Best Pract Res Clin Gastroenterol; 2006; 20(5):829-42. PubMed ID: 16997164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment for Barrett's oesophagus.
    Rees JR; Lao-Sirieix P; Wong A; Fitzgerald RC
    Cochrane Database Syst Rev; 2010 Jan; 2010(1):CD004060. PubMed ID: 20091557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Surveillance for Barrett's oesophagus: worthwhile?].
    Kastelein F; Kuipers EJ
    Ned Tijdschr Geneeskd; 2012; 156(49):A5497. PubMed ID: 23218039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of diagnosis, surveillance, and treatment of Barrett's oesophagus on health-related quality of life.
    Britton J; Keld R; Prasad N; Hamdy S; McLaughlin J; Ang Y
    Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):57-65. PubMed ID: 28970029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medical decision analysis of endoscopic surveillance of Barrett's oesophagus to prevent oesophageal adenocarcinoma.
    Sonnenberg A; Soni A; Sampliner RE
    Aliment Pharmacol Ther; 2002 Jan; 16(1):41-50. PubMed ID: 11856077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening and Surveillance for Barrett's Esophagus: Is It Cost-Effective?
    Inadomi JM; Saxena N
    Dig Dis Sci; 2018 Aug; 63(8):2094-2104. PubMed ID: 29948571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer risk in Barrett's oesophagus.
    Dias Pereira A; Suspiro A; Chaves P
    Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):915-8. PubMed ID: 18049157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett's esophagus.
    Gordon LG; Mayne GC; Hirst NG; Bright T; Whiteman DC; ; Watson DI
    Gastrointest Endosc; 2014 Feb; 79(2):242-56.e6. PubMed ID: 24079411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Barrett's mucosa, Barrett's dysplasia and Barrett's carcinoma: diagnostic endoscopy without biopsy-taking does not suffice.
    Vieth M; Stolte M
    Dis Esophagus; 2000; 13(1):23-7. PubMed ID: 11005327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus.
    Vij R; Triadafilopoulos G; Owens DK; Kunz P; Sanders GD
    Gastrointest Endosc; 2004 Nov; 60(5):739-56. PubMed ID: 15557950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surveillance in Barrett's esophagus: a failed premise.
    Inadomi JM
    Keio J Med; 2009 Mar; 58(1):12-8. PubMed ID: 19398879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnosis and treatment of Barrett's oesophagus. A general survey.
    Petrakis IE; Sciacca V; Iascone C
    Acta Chir Belg; 2001; 101(2):53-8. PubMed ID: 11396051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.